摘要
目的：探讨奥氮平联合丙戊酸钠治疗难治性精神分裂症的疗效及安全性。方法：将62例难治性精神分裂症患者随机分为2组，奥氮平联合丙戊酸钠组（研究组）33例，单用奥氮平组29例（对照组），采用PANSS、TESS量表评定观察疗效和不良反应12周。结果：治疗12周，研究组和对照组疗效相当；两组PANSS量表总分，阳性量表分，阴性量表分，一般精神病理量表分于4周末均较治疗前有显著性下降（P〈0．01），研究组阳性量表分自第2周起明显优于对照组（P〈0．05），且不良反应较少，程度较轻（P〈0．05）；研究组奥氮平用量较对照组少，经济费用明显偏低。结论：奥氮平合并丙戊酸钠治疗难治性精神分裂症疗效肯定，安全性高，耐受性、依从性较好。
Objective：To explore the curative effects and safety of Olanzapine with Valproate in refractory schizophrenia. Methods：62 patients with refractory schizophrenia were randomly divided into experiential group （n = 33, receiving Lanzopine with Valproate） and control group （n = 29, receiving Olanzapine only） for 12 weeks. The clinical efficiencies were assessed with the Posi- tive and Negative Syndrome Scale （PANSS） and the adverse effects assessed with the Treatment Emergent Symptom Scale （TESS） before treatment and the end of the 2nd, 4th, 8th, and 12th week treatment. Results： At the end of 12 weeks, the efficiencies of both groups were equivalent （P 〈 0.05）. Compared with pretreatment, the total scores of the PANSS, the Positive, the Negative and the general psychopathological factors were lowered significantly. But the scores of the experiential group were confidential lower than that of control group since the end of 2 weeks. As well as the adverse effects were less and milder. But the dose and fee per day in experience group were smaller than that of control. Conclusions： The curative effects and safety of Oianzopine with Valproate for refractory schizophrenia are sure, safe and better compliance.
出处
《中国民康医学》
2009年第5期455-457,共3页
Medical Journal of Chinese People’s Health
